Actelion to host Conference Call / Audiocast on SERAPHIN Study Results

Mon Apr 30, 2012 1:06am EDT

* Reuters is not responsible for the content in this press release.

Actelion Pharmaceuticals Ltd / Actelion to host Conference Call / Audiocast on SERAPHIN Study Results . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

Dear member of the investment community,

Actelion Ltd will host a Conference Call / Audiocast on the positive SERAPHIN Study Results today, on Monday, 30 April 2012, at 14.00 CET / 13.00 BST / 08.00 a.m. EST.

The company announced today that its endothelin receptor antagonist, macitentan met the primary endpoint in the pivotal Phase III outcome study in patients with pulmonary arterial hypertension.


30 April 2012 14.00  - 15.00 hrs Basel (CET)
13.00  - 14.00 hrs UK (BST)
08.00  - 09.00 a.m. US (EST)

Conference Call Connect #:

Dial-in participants should start calling the number below 10-15 minutes before the conference is due to start.

Dial: Europe: +41 (0)44 580 00 74
UK: +44 (0)203 367 94 53
US: +1 866 907 59 23

Participant's mode:
Listen-Only with possibility to open individual lines during Q&A session. Participants will be asked for their Name and Company.

Audiocast Replay:

Audiocast participants should visit the Actelion website 10-15 minutes before the conference is due to start.

Participant's mode:
Listen only

Audiocast Access:

The archived Investor Audiocast will be available for replay through approximately 60 minutes after the call has ended.

For further information please contact:

Roland Haefeli
Senior Vice President, Head of Investor Relations & Public Affairs                     
+41 61 565 62 62
+1 646 737 49 72

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Actelion Pharmaceuticals Ltd via Thomson Reuters ONE


--- End of Message ---

Actelion Pharmaceuticals Ltd
Gewerbestrasse 16 Allschwil Switzerland

ISIN: CH0010532478;

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.